期刊文献+

西格列汀联合二甲双胍治疗磺脲类药物失效老年糖尿病患者的临床观察 被引量:15

下载PDF
导出
摘要 目的:针对黄脲类药物继发性失效的老年2型糖尿病患者改用西格列汀联合二甲双胍对比改用单独预混胰岛素皮下注射治疗的疗效观察。方法:对黄脲类药物继发失效的34例老年糖尿病患者,随机分为两组,对照组单用忧泌乐25R皮下注射,1-2次/d,治疗组口服西格列汀100 mg,联合二甲双胍,0.25-1.5 g/d口服。观察12周前后两组空腹血糖、餐后2 h血糖、糖化血红蛋白、空腹C肽、餐后2 h C肽的变化。结果:磺脲类失效的老年糖尿病患者使用西格列汀联合二甲双胍治疗降糖效果与单用预混胰岛素治疗相当,且可减少低血糖发生。结论:使用预混胰岛素优泌乐25R或西口服格列汀联合二甲双胍治疗老年黄脲类药物继发性失效均有较好疗效,西格列汀组低血糖发生率低、使用方便、不增加体重,且可能改善胰岛β细胞功能。
出处 《吉林医学》 CAS 2013年第30期6279-6280,共2页 Jilin Medical Journal
  • 相关文献

参考文献5

二级参考文献13

  • 1Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus[J].Drugs,2005,65(3):385-411.
  • 2Setter SM, Iltz JL, Thams J, et al. Metformin hydrochloride in the treatment of type 2 diabetes mellitus~a clinical review with a focus on dual therapy[J]. Clin Ther, 2003, 25 (12): 2991- 3026.
  • 3Hunda] RS, Inzucchi SE. Metformin: new understandings, new uses[J]. Drugs, 2003,63 (18):1879-1894.
  • 4Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies ( UKPDS 49 ). UK Prospective Diabets Study (UKPDS) Group[J]. JAMA, 1999,281 (21 ) : 2005-2012.
  • 5Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-E 3- ( trifluoromethyl)-5,6-dihydro[ 1,2,4] triazolo [4,3-a3 pyrazin -7(8H)-yl] -1-(2, 4, 5-trifluorophenyl) butan 2-amine:a potent,orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diahetes[J].J Med Chem, 2005,48 ( 1 ): 141-151.
  • 6Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyi peptidase-4 inhibitor sitaglipin as monotherapy in patients with type 2 diabetes mellitus[J]. Diabetolgia, 2006,49 (11) :2564-2571.
  • 7Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled on metformin alone [J]. Diabetes Care, 2006, 29 (12) :2638-2643.
  • 8Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptiddyl peptidase-4 inhibitor satagliptin as monotherapy on glycemie eontrol in patients with type 2 diabetes[J]. Diabetes Care,2006,29(12) :2632-2637.
  • 9Rosenstock J, Brazg R, Andryuk P,et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitaglipin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24 week, multicenter, randomized, double-Blind, placebo-controlled parallel group study[J]. Clin Ther,2006,28(10): 1556-1568.
  • 10Nuck MA,Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glueagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients[J]. Diabeologia, 1993,36 (8):741-744.

共引文献37

同被引文献108

引证文献15

二级引证文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部